Table 5 Patients characteristics and findings of the included case reports
Variable |  | N (%) or Mean ± SD | Variable |  | N (%) or Mean ± SD |
|---|---|---|---|---|---|
Number | Cases | 57 | Clinical features | Fever | 41 (71.9%) |
Articles | 20 | Cough | 34 (59.6%) | ||
Countries of the cases reported | China | 28 (49.1%) | Â | Fatigue | 14 (25.6%) |
Italy | 12 (21.0%) | Myalgia | 12 (21.0%) | ||
USA | 6 (10.5%) | Headache | 5 (8.8%) | ||
Norway | 3 (5.3%) | Dizziness | 2 (3.5%) | ||
Iran | 2 (3.5%) | Taste impairment | 11 (19.3%) | ||
Spain | 2 (3.5%) | Smell impairment | 13 (22.8%) | ||
France | 1 (1.8%) | Encephalopathy features | 5 (8.8%) | ||
Germany | 1 (1.8%) | Weakness/ paralysis | 7 (12.3%) | ||
Japan | 1 (1.8%) | Altered reflexes | 3 (5.3%) | ||
UK | 1 (1.8%) | Altered sensationc | 5 (8.8%) | ||
Age (Years) |  | 59.5 ± 20.2 | Ataxia or abnormal gait | 1 (1.8%) | |
Gender | Male | 38 (66.6%) | Facial weakness | 4 (7%) | |
Female | 19 (33.3%) | Neck pain/ rigidity | 2 (3.5%) | ||
Comorbidities | Any | 24 (42.1%) | Number of neurological manifestations | None | 20 (35.0%) |
DM | 7 (12.3%) | 1–2 | 27 (47.3%) | ||
Hypertension | 13 (22.8%) | > 3 | 10 (17.5%) | ||
Cardiovascular diseases | 9 (15.7%) | Neurological complications | Any | 12 (21.0%) | |
Neurological diseases | 8 (14.0%) | GBS | 6 (10.5%) | ||
Chronic liver diseases | 3 (5.2%) | Encephalitis | 2 (3.5%) | ||
Pulmonary diseases | 5 (8.8%) | Seizure | 2 (3.5%) | ||
Malignancy or cancer | 1 (1.8%) | Cerebral Hemorrhage | 1 (1.8%) | ||
Chronic kidney disease | 4 (7%) | Myelitis | 1 (1.8%) | ||
ICU | Yes | 16 out of 28 (57.1%) | Rhabdomyolysis | 1 (1.8%) | |
No | 12 out of 28 (42.8%) | Onset (Days)a | 7.25 ± 2.43 | ||
Onset (Days) a | 7.7 ± 2.9 | Imaging | CT/MRI changes | 6 (10.5%) | |
Ventilator | Yes | 11 out of 31 (35.4%) | CSF | Increased protein | 5 (8.8%) |
No | 20 out of 31 (64.5%) | SARS-CoV-2 RNA in CSF | 1 (1.8%) | ||
Onset (Days) a | 7 ± 2.49 | EEG | Temporal slowing and sharp waves | 1 (1.8%) | |
Severity of COVID-19 | Asymptomatic | 3 (5.3%) | Nerve conduction study/EMG | Demyelinating or Axonal patterns | 6 (10.5%) |
Non-severe | 19 (33.3%) | Neurology-related management | Â | 12 (21%) | |
Severe | 30 (52.6%) | Neurological outcome | Morbidity/ disability | 4 out of 16(25%) | |
COVID-19 disease outcome | Death | 20 out of 45(44.4%) | Recovery/ Improvement | 10 out of 16(62.5%) | |
Discharged/ Recovery | 18 out of 45(40%) | Still hospitalized | 2 out of 16(12.5%) | ||
Still hospitalized | 7 out of 45(15.5%) | Onset (Days)a,b | 15.5 (2.5) |